SREBP-Mediated Lipid Regulation in the Intestine

SREBP 介导的肠道脂质调节

• 批准号: 8917213
• 负责人: Luke James Engelking
• 金额: $ 14.72万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8917213
• 关键词: Address; Adipose tissue; Animals; Binding; Binding Proteins; Biology; Blood; Carbohydrates; Cardiovascular Diseases; Cells; Cessation of life; Cholesterol; Cholesterol Homeostasis; Cirrhosis; Complex; Development; Diet; Dietary Cholesterol; Disease; Dyslipidemias; Endoplasmic Reticulum; Enterocytes; Enzymes; Family; Fatty Liver; Feedback; Food; Genes; Genetic; Goals; Golgi Apparatus; Grant; Health; Hepatic; Homeostasis; Hydroxymethylglutaryl-CoA reductase; Hyperlipidemia; Hypertriglyceridemia; Insulin Resistance; Intestines; Knowledge; LDL Cholesterol Lipoproteins; Laboratories; Lead; Lipid Synthesis Pathway; Lipids; Liver; Liver diseases; Low Density Lipoprotein Receptor; Low-Density Lipoproteins; Mediating; Membrane; Membrane Proteins; Mentors; Metabolic syndrome; Metabolism; Molecular; Morbidity - disease rate; Mus; Myocardial Infarction; Names; National Institute of Diabetes and Digestive and Kidney Diseases; Nuclear; Obesity; Organ; Pathogenesis; Pathologic; Pathway interactions; Peptide Hydrolases; Pharmaceutical Preparations; Plasma; Play; Proteins; Proteolysis; Regulation; Research; Response Elements; Role; SRE-2 binding protein; Site; Small Intestines; Sterols; Stress; Therapeutic Agents; Tissues; Triglycerides; United States; Work; activating transcription factor; cholesterol control; cholesterol transporters; combat; drug development; ezetimibe; hypercholesterolemia; in vivo; insight; interest; lipid disorder; lipid metabolism; mortality; mouse model; non-alcoholic fatty liver; novel; novel therapeutics; prevent; response; site-1 protease; transcription factor; uptake

DESCRIPTION (provided by applicant): High cholesterol diets raise the level of Low Density Lipoprotein (LDL) cholesterol in blood and produce heart attacks, thereby causing one-third of all deaths in the United States. The key factors that control LDL uptake and cholesterol synthesis are called sterol response element binding proteins, or SREBPs. My mentors, Brown and Goldstein, discovered SREBPs in 1993 and in the intervening years described how cells turn on and off SREBPs. SREBPs are controlled by two other factors, named Scap and Insig. Scap and Insig sense cholesterol levels in the cell. When cholesterol is high, Insigs block Scap and prevent SREBPs from being activated. When cholesterol is low, the blocking effect of Insigs is lost and Scap activates SREBPs so that they can turn on all of the genes needed to synthesize lipids or take up LDL cholesterol from the blood. Although all organs are capable of cholesterol synthesis and LDL uptake, the most important organs are the liver and small intestine. Our laboratory showed years ago that when SREBPs in the liver are not functioning properly it can lead to high blood cholesterol. Regulation of cholesterol in the small intestine is poorly understood. The interior lining of the intestines is made from cells called enterocytes. They are unique in that, in addition to getting cholesterol from endogenous synthesis and LDL uptake as do all other cells, they also absorb cholesterol from the diet. A large portion of lipids that end up elsewhere in the body originated in enterocytes, where they were newly synthesized or absorbed from food. Therefore, the intestine is critically important in the control of cholesterl homeostasis, and so the research aimed at understanding intestinal biology and the control of metabolism supported by the NIDDK has far-reaching implications. My recent studies were the first to look at SREBP function in enterocytes, and the results indicated that SREBPs provide key control of cholesterol in the small intestines. The aims of this proposal expands on these studies and outline a plan using genetically modified mice in which I will inactivate Insig (causin SREBP activation) or Scap (causing SREBP inactivation) in the intestine. The primary goal is to understand the function of SREBPs in the intestines by examining the consequences of turning them on or off. The second goal is to determine whether lipid synthesis in the intestines contributes to the buildup of lipids in other tissues associated with certain diseases: excess lipi in the blood, or hyperlipidemia, causes heart attacks. Excess lipid in the liver, or fatty liver disease, causes cirrhosis. Excess lipid in adipose tissue, or obesity, causes a huge number of health problems. By turning on or off SREBPs in the intestines of mice that also have hyperlipidemia, obesity, or fatty liver, we will find out if SREBPs contribute to these diseases. The ultimate goal is to determine if blocking SREBPs in the intestine can be employed to develop new drugs to combat hyperlipidemia, fatty liver, and obesity.

描述（由申请人提供）：高胆固醇饮食提高血液中的低密度脂蛋白（LDL）胆固醇水平并导致心脏病发作，从而导致美国三分之一的死亡。控制LDL摄取和胆固醇合成的关键因素被称为固醇反应元件结合蛋白（SREBPs）。我的导师布朗和戈尔茨坦在1993年发现了SREBPs，并在这期间描述了细胞如何开启和关闭SREBPs。srebp受另外两个因素控制，即Scap和insg。Scap和insing感知细胞中的胆固醇水平。当胆固醇高时，insg会阻断Scap并阻止srebp被激活。当胆固醇水平较低时，insg的阻断作用消失，Scap激活srebp，这样它们就可以开启合成脂质或从血液中吸收低密度脂蛋白所需的所有基因。虽然所有器官都能合成胆固醇和吸收低密度脂蛋白，但最重要的器官是肝脏和小肠。我们的实验室几年前就证明，当肝脏中的SREBPs功能不正常时，它会导致血液中的高胆固醇。小肠中胆固醇的调节是